StreetInsider.com News Articles

Form PRE 14A Pyxis Oncology, Inc. For: Oct 09

Fri, 09 Oct 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20261009/27172247.html

Form SCHEDULE 13G/A Pyxis Oncology, Inc. Filed by: GordonMD Global Investments LP

Fri, 09 Oct 2026 14:49:00 -0400

si-local-file:///var/storage/secattach/20261009/27171140.html

Form 4/A Pyxis Oncology, Inc. For: Oct 01 Filed by: Gordon Craig D

Fri, 09 Oct 2026 14:40:00 -0400

si-local-file:///var/storage/secattach/20261009/27171081.html

Form SCHEDULE 13G Pyxis Oncology, Inc. Filed by: Coastlands Capital LP

Mon, 05 Oct 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20261005/27147135.html

Form SCHEDULE 13G/A Pyxis Oncology, Inc. Filed by: GordonMD Global Investments LP

Fri, 02 Oct 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20261002/27139232.html

Form 4 Pyxis Oncology, Inc. For: Oct 01 Filed by: Gordon Craig D

Fri, 02 Oct 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20261002/27139242.html

Pyxis Oncology closes public offering with $110M in upfront proceeds

Fri, 02 Oct 2026 07:00:17 -0400

Pyxis Oncology, Inc. (Nasdaq: PYXS) closed a registered public offering on October 1, 2026, generating approximately $110.0 million in upfront gross proceeds before deducting underwriting discounts, commissions, and other expenses.

The offering consisted of 36,047,919 shares of common stock at $2.90 per share and pre-funded warrants to purchase 1,883,121 shares at $2.899 per warrant. Both the shares and warrants were accompanied by common warrants to purchase an aggregate of 49,310,352 shares of common stock at an exercise price of $3.50 per share, a 21% premium to the public offering price.

The common warrants are tied to the company's public disclosure of overall

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

Fri, 02 Oct 2026 07:00:00 -0400

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it closed its previously announced registered public offering (the "Offering") on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting discounts and commissions and other offering expenses. The Offering consisted of 36,047,919 shares of common stock at a public offering price of $2.90 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,883,121 shares of common stock

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

Fri, 02 Oct 2026 07:00:00 -0400

Form 8-K Pyxis Oncology, Inc. For: Sep 29

Thu, 01 Oct 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20261001/27137323.html

Form 424B5 Pyxis Oncology, Inc.

Thu, 01 Oct 2026 09:31:00 -0400

si-local-file:///var/storage/secattach/20261001/27132997.html

Pyxis Oncology prices public offering for ~$110M in gross proceeds

Wed, 30 Sep 2026 01:11:27 -0400

Pyxis Oncology, Inc. (Nasdaq: PYXS) has priced a registered public offering of shares of common stock, pre-funded warrants, and common warrants, with expected gross proceeds of approximately $110 million before deducting underwriting discounts, commissions, and offering expenses.

The offering includes 36,047,919 shares of common stock and 1,883,121 pre-funded warrants, each accompanied by common warrants to purchase up to 49,310,352 shares of common stock at an exercise price of $3.50 per share. The combined public offering price is $2.90 per share and accompanying common warrant, and $2.899 per pre-funded warrant and accompanying common warrant.

If all common warrants and pre-funded warrants are exercised

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

Wed, 30 Sep 2026 01:11:00 -0400

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previously announced registered public offering (the "Offering") of 36,047,919 shares of its common stock, or in lieu of common stock to certain investors, 1,883,121 pre-funded warrants to purchase shares of common stock, and accompanying common warrants to purchase 49,310,352 shares of common stock at an exercise price of $3.50. The combined public offering price for each share of common stock and accompanying common warrant is $2.90, and the combined public

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

Wed, 30 Sep 2026 01:11:00 -0400

Form 424B5 Pyxis Oncology, Inc.

Tue, 29 Sep 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260929/27123218.html

Pyxis Oncology stock falls on public offering announcement

Tue, 29 Sep 2026 16:54:26 -0400

Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) shares dropped 3.5% in after-hours trading Tuesday after the company announced a registered public offering of common stock and warrants.

The clinical-stage biopharmaceutical company said it commenced an offering of common stock, or pre-funded warrants in lieu of common stock to certain investors, along with accompanying common warrants to purchase shares of common stock.

The common warrants will become exercisable only upon stockholder approval of an amendment to increase the number of authorized shares of common stock. The warrants will expire upon the earlier of the fifth anniversary

Pyxis Oncology stock falls on public offering announcement

Tue, 29 Sep 2026 16:54:26 -0400

Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) shares dropped 3.5% in after-hours trading Tuesday after the company announced a registered public offering of common stock and warrants.

Pyxis Oncology launches public offering of stock and warrants

Tue, 29 Sep 2026 16:24:57 -0400

Pyxis Oncology, Inc. (Nasdaq: PYXS) announced a registered public offering of shares of common stock, or pre-funded warrants in lieu of common stock, accompanied by common warrants to purchase shares of common stock, according to a company statement.

The Boston-based clinical-stage biopharmaceutical company said all securities in the offering will be sold by Pyxis Oncology. Each share of common stock and each pre-funded warrant will be sold together with a common warrant to purchase one share of common stock.

The common warrants will become exercisable only upon stockholder approval of an amendment to the company's certificate of incorporation to increase authorized shares

Pyxis Oncology terminates $150M ATM stock offering program

Tue, 29 Sep 2026 16:24:40 -0400

Pyxis Oncology (NASDAQ: PYXS) has terminated a continuous at-the-market stock offering program that had been set up to raise up to $150 million, according to a filing with the Securities and Exchange Commission.

The company had entered into a Sales Agreement with Leerink Partners LLC on November 26, 2025, under which it could sell shares of common stock through at-the-market transactions. As of the termination date, no shares had been sold under the agreement.

The termination reduces the maximum aggregate gross sales price under the prospectus supplement from $150 million to $0, freeing up corresponding capacity under the company's Form S-3 registration

Pyxis Oncology terminates $150M ATM stock offering program

Tue, 29 Sep 2026 16:24:40 -0400

The termination reduces the maximum aggregate gross sales price under the prospectus supplement from $150 million to $0, freeing up corresponding capacity under the company's Form S-3 registration

Pyxis Oncology Announces Proposed Public Offering

Tue, 29 Sep 2026 16:24:00 -0400

BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the "Offering") of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase shares of common stock. Each share of common stock and each pre-funded warrant will be sold together with a common warrant to purchase one share of common stock.

The common warrants

Pyxis Oncology Announces Proposed Public Offering

Tue, 29 Sep 2026 16:24:00 -0400

The common warrants

Form 424B5 Pyxis Oncology, Inc.

Tue, 29 Sep 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260929/27122741.html

Pyxis Oncology Inc. (PYXS) PT Raised to $8 at H.C. Wainwright

Thu, 10 Sep 2026 06:58:02 -0400

(Updated - September 10, 2026 6:58 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Pyxis Oncology Inc. (NASDAQ: PYXS) to $8.00 (from $7.00) while maintaining a Buy rating.

The analyst commented: "On September 9, 2026, Pyxis Oncology reported updated data (cut-off: August 18, 2026) from its ongoing global multicenter Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). Most patients were in the third line at enrollment (N=33 efficacy evaluable; N=35 safety evaluable), and the enrollment criteria were broad, allowing assessment across key subgroups: HPV-positive

Pyxis Oncology Inc. (PYXS) PT Raised to $8 at H.C. Wainwright

Thu, 10 Sep 2026 06:58:02 -0400

(Updated - September 10, 2026 6:58 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Pyxis Oncology Inc. (NASDAQ: PYXS) to $8.00 (from $7.00) while maintaining a Buy rating.